Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have received a consensus rating of “Buy” from the ten analysts that are presently covering the stock. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $41.40.
Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Blueprint Medicines Corp from a “buy” rating to a “hold” rating in a report on Tuesday. Wedbush upped their price objective on shares of Blueprint Medicines Corp from $43.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, April 5th. Morgan Stanley assumed coverage on shares of Blueprint Medicines Corp in a report on Wednesday, February 15th. They issued an “overweight” rating and a $45.00 price objective for the company. Canaccord Genuity upped their price objective on shares of Blueprint Medicines Corp from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, April 4th. Finally, JMP Securities assumed coverage on shares of Blueprint Medicines Corp in a report on Wednesday, March 22nd. They issued an “outperform” rating and a $46.00 price objective for the company.
Blueprint Medicines Corp (NASDAQ:BPMC) traded down 1.07% during midday trading on Friday, hitting $45.51. 178,521 shares of the stock traded hands. Blueprint Medicines Corp has a one year low of $13.27 and a one year high of $47.40. The company has a 50-day moving average price of $41.28 and a 200 day moving average price of $34.00. The stock’s market cap is $1.51 billion.
Blueprint Medicines Corp (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, March 9th. The biotechnology company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.01. The business earned $7.69 million during the quarter, compared to analyst estimates of $6.31 million. Blueprint Medicines Corp had a negative net margin of 270.30% and a negative return on equity of 55.22%. The company’s quarterly revenue was up 65.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.58) earnings per share. Equities research analysts anticipate that Blueprint Medicines Corp will post ($3.29) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Blueprint Medicines Corp (BPMC) Given Consensus Rating of “Buy” by Brokerages” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/21/blueprint-medicines-corp-bpmc-receives-average-rating-of-buy-from-analysts-updated.html.
In other news, major shareholder Mark J. Levin sold 30,000 shares of the company’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $40.88, for a total value of $1,226,400.00. Following the transaction, the insider now owns 116,444 shares in the company, valued at approximately $4,760,230.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Rock Ventures Ii L.P. Third sold 1,000,000 shares of the company’s stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $35.28, for a total value of $35,280,000.00. The disclosure for this sale can be found here. 3.93% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of the stock. Verde Servicos Internacionais S.A. acquired a new position in shares of Blueprint Medicines Corp during the first quarter worth $199,000. Highbridge Capital Management LLC acquired a new position in shares of Blueprint Medicines Corp during the fourth quarter worth $379,000. Teachers Advisors LLC increased its position in shares of Blueprint Medicines Corp by 2.7% in the fourth quarter. Teachers Advisors LLC now owns 32,932 shares of the biotechnology company’s stock worth $924,000 after buying an additional 881 shares in the last quarter. Norges Bank purchased a new position in Blueprint Medicines Corp during the fourth quarter worth approximately $701,000. Finally, Opaleye Management Inc. increased its position in Blueprint Medicines Corp by 12.1% in the fourth quarter. Opaleye Management Inc. now owns 880,000 shares of the biotechnology company’s stock worth $24,684,000 after buying an additional 95,000 shares in the last quarter. Institutional investors own 59.51% of the company’s stock.
About Blueprint Medicines Corp
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with MarketBeat.com's FREE daily email newsletter.